Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Oxaliplatin 296Fluorouracil 272Bevacizumab 236Gemcitabine 235Leucovorin 212Capecitabine 204pembrolizumab 202Nivolumab 156Irinotecan 156Cisplatin 150Specimen Handling 143Magnetic Resonance Spectroscopy 130130-nm albumin-bound paclitaxel 115Paclitaxel 109durvalumab 104Cetuximab 102Radiotherapy 96atezolizumab 92Biopsy 92Drug Therapy 91Albumin-Bound Paclitaxel 78tislelizumab 77Taxes 73lenvatinib 68Folfox protocol 68Carboplatin 66Blood Specimen Collection 61regorafenib 60trifluridine tipiracil drug combination 53Ipilimumab 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Community-Institutional Relations × Gastrointestinal × 1 year × Clear all
NCT06666192 2025-12-24

The Ohio State University (OSU) SCREEN Community Program

Ohio State University Comprehensive Cancer Center

Phase NA Recruiting
2,067 enrolled
BreastGastrointestinalGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡